Cat:GMP-h-HBP
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-h-HBP Categories , Tag

Product Details

Genemedi produces core diagnostic ingredients for test of Inflammation/autoimmune/inflammatory disease (inflammation/autoimmune/ inflammatory disease) and related syndrome. GeneMedi offers paired diagnostics grade Heparin-binding protein (HBP) antibodies (monoclonal antibody, mab) and antigens for Inflammation/autoimmune/inflammatory disease (inflammation/autoimmune/ inflammatory disease) rapid test kit of Heparin-binding protein (HBP) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Inflammation/autoimmune/inflammatory disease (inflammation/autoimmune/ inflammatory disease ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.The incidence of sepsis increases with ageing, rise in cancer incidence and popularity of invasive medical operations.1 2 Rapid detection and optimised treatment are the keys to successful treatment of sepsis.3 To facilitate earlier recognition and more timely management of patients with sepsis or those at risk of developing the condition, the European Society of Intensive Care Medicine and Society of Critical Care Medicine published new diagnostic criteria for sepsis and septic shock.4 Nevertheless, due to time delay, low sensitivity and lack of specificity,5 the existing diagnosis indicators such as microbial culture, complete blood count, and levels of procalcitonin (PCT) and C reactive protein (CRP) are inadequate for timely clinical diagnosis of sepsis and septic shock. Heparin-binding protein (HBP) is precomposed and mainly exists in the azurophilic granules (almost 74% in content) and secretory vesicles (almost 18% in content) of neutrophils. Azurophilic granules show low tendency to be released from cells, and they are only released when neutrophils infiltrate tissues.6 The release of easily mobilised HBP from secretory vesicles has important functions during early events in inflammatory processes. HBP works by activating various cell types.7 Previous studies have shown that the plasma HBP level is significantly elevated in sepsis combined with organ dysfunction, which is the best probe for the progression of sepsis.3 8 Given the capacity of HBP to identify infection and vascular leakage in patients, it is also an interesting candidate marker to monitor patients with sepsis and septic shock.

Product Description

Cat No. of Pruducts

GMP-h-HBP-Ag01:Recombinant Human HBP Protein

Product Name

Recombinant Human HBP Protein

Target

Heparin-binding protein

Alias of Target/Biomarker

#N/A

Expression platform

E.coli

Isotypes

Recombinant Antigen

Bioactivity validation

Heparin-binding protein (HBP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HBP level test of Inflammation/autoimmune/inflammatory disease (inflammation/autoimmune/ inflammatory disease) and related syndrome evaluation

Tag

His

Products description

Recombinant Human HBP Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Genemeidi Omicron Variant Products
test
Previous slide
Next slide

Cat No. of Pruducts

GMP-h-HBP-Ab01,GMP-h-HBP-Ab02:Anti-Human HBP mouse monoclonal antibody (mAb)

Product Name

Anti-Human HBP mouse monoclonal antibody (mAb)

Target

Heparin-binding protein (HBP)

Alias of Target/Biomarker

#N/A

Expression platform

Hybridoma

Isotypes

Mouse IgG

Bioactivity validation

Human Heparin-binding protein (HBP) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Heparin-binding protein (HBP) antibodies in HBP level test of Inflammation/autoimmune/inflammatory disease (inflammation/autoimmune/ inflammatory disease) and related syndrome evaluation.

Tag

mFc

Products description

Anti-Human HBP mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other Heparin-binding protein (HBP) antibodies.

Reconized/Reactive Species

Human

Purity

Purity: ≥95% (SDS-PAGE)

Application

ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT

Formulation

Supplied as a 0.2 μM filtered solution of PBS,PH7.4.

Storage

Store at? -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1

Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.